key: cord-0027681-9iykcluq
authors: Shahroz, Mir Mohammad; Sharma, Hemant Kumar; Altamimi, Abdulmalik S. A.; Alamri, Mubarak A.; Ali, Abuzer; Ali, Amena; Alqahtani, Safar; Altharawi, Ali; Alabbas, Alhumaidi B.; Alossaimi, Manal A.; Riadi, Yassine; Firoz, Ahmad; Afzal, Obaid
title: Novel and Potential Small Molecule Scaffolds as DYRK1A Inhibitors by Integrated Molecular Docking-Based Virtual Screening and Dynamics Simulation Study
date: 2022-02-09
journal: Molecules
DOI: 10.3390/molecules27041159
sha: bbc93dfd8611033731f2a8d96d9f52942122e1f3
doc_id: 27681
cord_uid: 9iykcluq

The dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) is a novel, promising and emerging biological target for therapeutic intervention in neurodegenerative diseases, especially in Alzheimer’s disease (AD). The molMall database, comprising rare, diverse and unique compounds, was explored for molecular docking-based virtual screening against the DYRK1A protein, in order to find out potential inhibitors. Ligands exhibiting hydrogen bond interactions with key amino acid residues such as Ile165, Lys188 (catalytic), Glu239 (gk+1), Leu241 (gk+3), Ser242, Asn244, and Asp307, of the target protein, were considered potential ligands. Hydrogen bond interactions with Leu241 (gk+3) were considered key determinants for the selection. High scoring structures were also docked by Glide XP docking in the active sites of twelve DYRK1A related protein kinases, viz. DYRK1B, DYRK2, CDK5/p25, CK1, CLK1, CLK3, GSK3β, MAPK2, MAPK10, PIM1, PKA, and PKCα, in order to find selective DYRK1A inhibitors. MM/GBSA binding free energies of selected ligand–protein complexes were also calculated in order to remove false positive hits. Physicochemical and pharmacokinetic properties of the selected six hit ligands were also computed and related with the proposed limits for orally active CNS drugs. The computational toxicity webserver ProTox-II was used to predict the toxicity profile of selected six hits (molmall IDs 9539, 11352, 15938, 19037, 21830 and 21878). The selected six docked ligand–protein systems were exposed to 100 ns molecular dynamics (MD) simulations to validate their mechanism of interactions and stability in the ATP pocket of human DYRK1A kinase. All six ligands were found to be stable in the ATP binding pocket of DYRK1A kinase.

Alzheimer's disease (AD) is distinguished by irremediable neurodegeneration as well as diminishing cognitive functions. About 60-70% cases of dementia is attributed structure of an indazole derivative (denoted as D15 in PDB ID: 2WO6) indicated that the indazole moiety interacts via two H-bonds with Leu241 and Glu239, along with a salt bridge that forms between the primary amine and the carboxylate side chain of Asp307 [39] . An indolo [3,2-c] quinoline-6-carboxylic acid analogue (4E2 in PDB ID: 4YLK) revealed the interactions in the ATP binding space of DYRK1A (IC 50 6 nM), via (i) a salt bridge amid the carboxylate group of 4E2 and the amine of Lys188, (ii) water interceded hydrogen bonds with Ser242 & Asp307, and (iii) flipped P-loop residue Phe170 forming pi-pi hydrophobic interactions with the inhibitor. In addition, the iodine at position 10 was found located nearby gatekeeper (gk) Leu241 at a distance of 3.3 Å [40] . A hydroxyl acetamido benzothiazole (denoted as QIV in PDB ID: 5A3X) revealed active site binding (DYRK1A IC 50 400 nM) with the acetamide group forming hydrogen bond to the catalytic Lys188, and the 5-OH group forming hydrogen bond with the gk Leu241 [41] . Czarna et al., screened their in-house library of 1000 compounds, and reported 9 potential DYRK1A inhibitors (Ki values in the range of 104 to 1680 nM) with different core structures [42] . Weber et al., recently reported several 2-methyl-3H-imidazo [4,5-b] pyridin-5-yl]pyridine-2,6-diamine derivatives, among them the most promising and selective DYRK1A inhibitor has an IC 50 value of 5 nM (DYRK2 IC 50 = 195 nM) [43] . The gene for DYRK1A is found to be located within DSCR on human chromosome 21, and studies revealed that upregulation of DYRK1A is the key factor responsible for cognitive decline in patients of AD and DS [14, 15] . Since current symptomatic treatments for cognitive deficiencies are limited and inefficient, inhibition of DYRK1A function in the brain by small molecules offers a good opportunity for pharmaceutical interference for neurodegeneration associated with AD and DS. In this report, we identified some novel and selective potential DYRK1A inhibitors with different structural scaffolds through a comprehensive molecular docking-based virtual screening approach, validated by molecular dynamics simulations. The identified inhibitors were found to have a good in silico physicochemical, pharmacokinetic and toxicity profile. The workflow adopted to identify novel, potent and selective DYRK1A inhibitors is depicted in Figure 2 . 

The downloaded molMall database containing 15,381 chemically diverse structures was checked for any duplicates by using OpenBabel (ver. 3.0.0) and found to be unique without any duplicates. It was prepared for docking-based virtual screening by the application LigPrep (ver. 3.4) . The resulting docking library consisting of 54,594 structures was utilized for comprehensive molecular docking-based virtual screening against a set of DYRK1A protein kinases.

In order to increase the accuracy of the results, five DRYK1A protein crystal structures (PDB IDs: 3ANQ, 4AZE, 2WO6, 4YLK and 5A3X), available in the protein data bank (PDB) from diverse reputed laboratories and reported in different timelines as having different resolutions, were used for docking-based virtual screening. The difference in the crystal structure of these five DYRK1A kinases were visualized by superimposing with the help of the PyMOL Molecular Graphics System (v1.8.4.0). A slight variation near αC helix and β1, β2 and β3 sheets were observed among the crystal structures and is depicted in Figure 3 . The ATP binding space in DYRK1A kinase protein, essential for the development of selective inhibitors, is a conserved region and consists of Phe238 (gatekeeper; gk), Glu239 (gk+1), Leu241 (gk+3), Lys188 (catalytic), Phe170, Ser242, Asn292, and Asp307 amino acid residues [33, [38] [39] [40] [41] . In order to find out selective DYRK1A inhibitors, the potent and common ligands obtained after docking-based virtual screening were also screened for their binding affinity with the other twelve related protein kinases [PDB IDs: 

Each of the co-crystallized ligands, viz. EHB (of 3ANQ), 3RA (of 4AZE), D15 (of 2WO6), 4E2 (of 4YLK), and QIV (of 5A3X) of the DYRK1A protein kinase, were docked into the ATP pocket of their corresponding pdb structures by Glide extra precision (XP) docking. The docked ligand's top poses based on their scores and interactions with the active site residues were aligned with the co-crystallized poses in order to validate the docking protocol. The heavy atom RMSD for EHB, 3RA, D15, 4E2, and QIV were found to be 0.742 Å, 0.932 Å, 0.978 Å, 0.573 Å and 0.466 Å, respectively ( Figure 4 ). The docking protocols that give conformations below a preselected value from the known poses (usually 1.5 or 2 Å depending on ligand size) are generally considered to have been implemented effectively [44] . The docking protocol was further validated by area under receiver operating characteristic (ROC) curves. Five active DYRK1A inhibitors (INDY, a lamellarin D analogue, a quinazoline amine derivative, Leucettine L41, and harmine) were used to generate 213 decoys (inactive inhibitors) by using DUDE webserver (A Database of Useful Decoys: Enhanced) [45] . All the 218 ligands were docked into the ATP binding pocket of five DYRK1A structures having PDB IDs viz. 2WO6, 3ANQ, 4AZE, 4YLK and 5A3X. The obtained results with docking scores of 218 ligands for each target structures were provided as an input file for the generation of ROC curves by the screening explorer webserver [46] . The ROC-AUC were found to be 0.948, 0.960, 0.975, 0.917 and 0.957, respectively for the five DYRK1A structures having PDB IDs 2WO6, 3ANQ, 4AZE, 4YLK and 5A3X. The ROC curve is depicted in Figure 5 . 

The library of compounds comprising 54,594 structures, prepared and obtained from LigPrep application, were exposed to docking-based virtual screening using the generated grid of five DYRK1A receptors, having PDB IDs viz. 3ANQ, 4AZE, 2WO6, 4YLK and 5A3X. HTVS with 1% output, SP docking with 10% output, and XP docking with 100% output options were selected. As a result, a total of 54 molecules were obtained from each subjected protein structure after docking-based virtual screening. A total of 41 ligand structures were found to be common in all output results. Out of these 41 molecules, a bis-indole indigoid scaffold (molMall ID: 19394) was already reported previously as a DYRK1A inhibitor, so this molecule was not included in further study [47] . A total of 40 structures were retained for further binding pattern analysis. Glide XP docking scores of the six final identified hit molecules and three known DYRK1A inhibitors is provided in Table 1 . Molecular contacts profiling for the identified six hit molecules and three known inhibitors in the selective ATP pocket of human DYRK1A (PDB ID: 3ANQ) is provided in Table 2 . 

The selected 40 ligand structures were selected for their binding pose investigation inside the ATP binding pocket of DYRK1A structures. Ligands having hydrogen bond interactions with key amino acid residues such as Ile165, Lys188 (catalytic), Glu239 (gk+1), Leu241 (gk+3), Ser242, Asn244, and Asp307 of the target protein were retained. Hydrogen bond interactions with Leu241 (gk+3) were considered key determinants for the selection and those having no interaction with the same were rejected [41] . Three-dimensional binding interactions (surface and cartoon view) and 2D binding pattern diagrams of the six final selected structures, along with reported known inhibitors (EHB, Harmine and EGCG), are depicted in Figures 6-8 , respectively. 

Binding free energies (∆G bind ) of selected ligand-protein complexes were calculated in order to remove false positive hits. A total of 32 ligands having ∆G bind less than −40 kcal/mol, and high Glide XP score less than −7.0, were retained for further docking with related DYRK1A related protein kinases in order to obtain selective inhibitors. The selection criteria were set keeping in mind the docking scores and ∆G bind values of two reported DYRK1A inhibitors, EHB and Harmine. Prime MM/GBSA binding free energy (kcal/mol) of the six final identified hit molecules and three known DYRK1A inhibitors is provided in Table 1 .

The selected 32 hits were docked by Glide XP docking in the ATP pocket of 12 DYRK1Arelated protein kinases viz. DYRK1B, DYRK2, CDK5/p25, CK1, CLK1, CLK3, GSK3β, MAPK2, MAPK10, PIM1, PKA, and PKCα in order to find the selectivity of the hit ligands [48] [49] [50] [51] [52] [53] [54] [55] [56] . Ligands with a Glide XP score less than −5.0 and Prime MM/GBSA ∆G bind below −40 kcal/mol were rejected and considered to be non-selective. Among them, the compound Quercetin (molMall IDs: 22067) was found to have a high Glide XP score and binding free energy, with 10 out of 12 kinases. A total of 15 structures were retained for further analysis of their physicochemical and pharmacokinetic properties. Glide XP scores and Prime MM/GBSA binding free energy (kcal/mol) of the six final identified hit molecules obtained after docking with related 12 protein kinases is provided in Table 3 . The heatmap analysis of the binding energy of six identified hits with all the studied kinases (DYRK1A and related kinases) are depicted in Figure 9 . Among the identified hits, molecules with molmall ID 15938 were found to have inhibitory potential towards DYRK2, GSK3β and MAPK10 kinases, while 11352 showed some affinity towards DYRK2 kinase. 

Ligands showing great variations from the qualifying limits for orally active CNS drugs were discarded [57] . Among them, the noticeable compounds with molMall IDs: 15677 (6,6 -dimethoxy-3,4 -biisoquinoline-7,7 -diol), 10992 ((1Z)-1H-naphtho[2,3-e]indole-1,2(3H)-dione-1-(phenylhydrazone)), 20271 (4-phenyl-1-(3a,4,7,7a-tetrahydro-1H-4,7methanoinden-1-yl)-1,2,4-triazolidine-3,5-dione), and 18976 (2-hydroxy-4-(4-hydroxyphenyl)-1H-phenalen-1-one). Structures having molMall IDs: 15938 and 19037, were found to have slight variation from the qualifying limits in terms of FOSA and PISA only, and thus were retained. A total of six structures were retained for further studies. The QP properties of the final six selected identified hit molecules are presented in Table S1 .

A preliminary evaluation of the toxicity viz. acute oral toxicity (LD 50 ), hepatotoxicity, mutagenicity, carcinogenicity, cellular toxicity, immunotoxicity, and toxicological pathways (nuclear receptor signalling and stress response pathways) of a chemical compound is of great importance in the discipline of drug discovery. In silico toxicity models can accurately predict the toxicity effects of chemicals and thus minimize time, costs and the need for animal testing. The computational toxicity webserver ProTox-II [58] was utilized to predict the toxicity profile of the six selected hits, along with the prediction accuracy, and are provided in Table S2 . Compounds having molMall IDs: 21830, 11352 and 21878 were found to be inactive and safe in terms of all the toxicological parameters. Compounds with molMall ID: 15938 were predicted to be carcinogenic (64% probability) and mutagenic (54% probability). Similarly, compounds with molMall ID: 19037 were predicted to be hepatotoxic (59% probability) and carcinogenic (72% probability). Compounds with molMall ID: 9539 were found to be the most toxic, with the prediction accuracy of 54.26% in terms of acute oral toxicity (LD 50 1 mg/kg), hepatotoxicity (56% probability) and carcinogenicity (55% probability). Despite the toxic probability of the three hits, all six of the final hits were included for further MD simulation study in order to confirm their stability in the ATP pocket of DYRK1A kinase, and indicate the probability of structural alterations in the scaffolds to find safer leads.

MD simulations were used to assess the interaction mechanism and stability of putative ligands in the ATP binding pocket of human DYRK1A kinase, using six docked ligand-protein complexes, with reference to the co-crystallized structure (EHB). The RMSD, Rg, RMSF, SASA, potential binding energy, hydrogen bond analysis, and PCA of the docked complexes were evaluated.

The simulated system's time to achieve structural equilibrium was calculated using RMSD. This is a crucial calculation that determines how a protein's molecular structure varies or changes. For the length of a 100 ns MD simulation, the equilibrium time for simulated protein-ligand complexes were determined using the backbone RMSD. Figure 10A shows the RMSD values of protein backbones that were computed. After 7.5 ns, all systems were equilibrated, and a substantial deviation in the protein backbone was seen during the first 10 ns simulation, which was predicted, given the abrupt shift in the protein environment. Complexes were then stabilized and demonstrated a constant state of dynamic behaviour for the period of the 100 ns simulation duration, with a tiny overall fluctuation range of RMSD 6.8 to 7.8 nm. With regard to the reference complex (EHB), all the complexes displayed a nearly identical RMSD fluctuation pattern. The RMSF parameter determines how much a residue contributes to a complicated structure's stability. The RMSF measurements revealed minor variations in the protein's backbone, with an average value of less than 0.5 nm ( Figure 10B ). Most of the disrupted residues in the reference complex are in the loop regions, away from the ligand-binding pocket location.

Rg was calculated by measuring the molecular volume and density of protein. The root mean square distance between each atom in the system and its centre of mass is the radius of gyration. All of the protein-ligand complexes (EHB, 9539, 11352, 15938, 19037 , 21830, and 21878) had steady Rg values between 2.21 and 2.31 nm, indicating protein stability, as the low values obtained over the 100 ns simulation duration suggested protein compactness and stable inhibitor binding ( Figure 11A ). The retention of stable conformation of smaller molecules inside the active pocket of the protein is dependent on hydrogen bonding [59] . Figure 11B The SASA was also calculated to evaluate the constancy of simulated systems, and to determine how much of the receptor area was exposed to the solvents. A larger SASA value represents the growth of protein volume during MD simulation. The interaction of the ligands in the active site can change SASA and protein folding [60] . The calculated SASA values observed for the ligands were between 188 and 196 nm 2 , reflecting that the binding does not affect the protein structure ( Figure 12A) , and also suggesting that complexes were stable after the binding of ligands inside the active site. The potential binding energy significantly contributes to the molecular interaction between the ligands and protein.

The higher negative values of the binding energy reflected that the targeted compound favourably interacted within the active site of the receptor. Ligands 21830 and 21878 are the most promising ones, since they showed higher negative binding energy ( Figure 12B ).

Essential dynamics (ED) or principal component analysis (PCA) is a reliable approach for classifying protein conformations and identifying massive, coordinated patterns of fluctuations from MD simulation trajectories. The PCA score plot ( Figure 13 ) revealed different clusters formations. Among them, 21830 (green) and 11352 (golden) are overlapped. The other complex exhibited significant differences by forming a distinct cluster. 

To predict the bioactivity, the structure of the identified six hits and reported three inhibitors were submitted to the Swiss Target Prediction webserver (http://www.swisstargetprediction.ch/; accessed on 23 January 2022) to determine their kinase inhibitory potential, provided in Table S3 . The co-crystallized ligand EHB showed the highest % kinase inhibition (86.7%) and the webserver accurately predicted the target as DYRK1A. This accurate prediction can be attributed to the presence of co-crystallized DYRK1A kinase structure (PDB ID: 3ANQ) in their database. However, for the rest two reported inhibitors of DYRK1A, harmine and EGCG, the % kinase inhibition was found to be 26.7% and 13.3%, respectively. This can be attributed to their non-selective nature. Among the identified hits, ligands having molmall ID 11352 and 9539 predicted to have the highest % kinase inhibition, 66.7% and 40%, respectively. The molinspiration webserver (https://www.molinspiration.com/cgi-bin/properties; accessed on 23 January 2022) was also used to predict the kinase inhibition potential of the molecules. A larger value of bioactivity score refers to the higher probability of the molecule being active. Ligands with molmall ID 11352 were predicted to have the highest kinase bioactivity score (+0.50), followed by harmine (+0.31). However, the bioactivity score for the co-crystallized ligand EHB was found to be −0.47 (Table S3 ).

The structure similarity of the six identified hits were compared with the co-crystallized ligand structures of DYRK1A and related kinases by ChemMine Web Tools (https:// chemminetools.ucr.edu/; accessed on 23 January 2022) to study the structure activity relationship, since similar structures have similar biological functions. The distance matrix (Z-scores) was computed and provided in Table S4 . The heatmap visualization of the distance matrix (Z-scores) was prepared by using the GraphPad Prism (version 9.1.0), depicted in Figure 14 . The same Z-scores were obtained for kinase, DYRK1A (PDB ID: 4AZE) and CLK3 (PDB ID: 3RAW), due to the presence of the same co-crystallized ligand, 3RA, in their ATP binding pocket. Molecules having molmall ID 21830 and 19037 were found to be more structurally similar to the co-crystallized ligand 3RA of DYRK1A (4AZE), while 11352 and 9539 showed maximum structure similarity with 4E2 of DYRK1A (4YLK). Molecule 15938 showed the highest structure similarity with ligands 3RA and D15 of DYRK1A among all the co-crystallized ligands studied. Molecule 21878 showed greater similarity with the ligand DBQ of CLK1 (1Z57), followed by 3RA of DYRK1A. Overall, from the results, it was concluded that the identified hits have the potential to inhibit other kinases such as DYRK2, CLK1 and CLK3, besides DYRK1A. 

The SyntheticAccessibiliyCli (Ambit-SA) software tool is a java program that computes synthetic accessibility (SA) scores for the given molecules ranging from 0 to 100. The value 100 denotes maximal synthetic accessibility and, hence, the molecule is easily synthesizable. This program includes molecular, stereo-chemical, and fused and bridged system complexities of the molecule and calculates SA scores on the basis of four molecular descriptors, representing different structural and topological features. Five out of six identified molecules were found to have satisfactory SA scores and are predicted to be easily synthesizable. The least SA score was found for the molecule having molmall ID 15938 (Table 4 ). 

As most of the previously discovered small molecules targeting β-secretase and γsecretase, have been failed in clinical trials, discovery of selective and potent DYRK1A inhibitors is an emerging research area for AD treatment [61] [62] [63] [64] . In this study, six novel and selective potential DYRK1A inhibitors with diverse structural scaffolds were identified by screening molMall database, consisting of rare, diverse and unique compounds, available commercially. The prepared molMall docking library, consisting of 54,594 structures, was utilized for molecular docking-based virtual screening against a set of five DYRK1A protein kinase crystal structures (PDB IDs: 3ANQ, 4AZE, 2WO6, 4YLK and 5A3X) in order to increase the accuracy of the results. As a result, a total of 54 small molecules were obtained from each subjected protein structure. A total of 41 ligand structures were found to be common in output results. Out of these 41 molecules, a bis-indole indigoid scaffold (molMall ID: 19394) was already reported previously, as a DYRK1A inhibitor [47] . A total of 40 structures were retained for further binding pattern analysis. The ATP binding pocket in DYRK1A kinase, essential for the binding of inhibitors, is a conserved region consisting of Phe238 (gatekeeper; gk), Glu239 (gk+1), Leu241 (gk+3), Lys188 (catalytic), Phe170, Ser242, Asn292, and Asp307 amino acid residues [33, [38] [39] [40] [41] . After MM/GBSA binding energy calculations, l of 32 ligands having ∆G bind less than −40 kcal/mol were retained and selected for further study. Identification of a potent and selective kinase inhibitor is a hectic and exciting task, since a large number of protein kinases share the same ATP binding site environment [65] . To find out a selective DYRK1A inhibitors, potent and common 32 ligands obtained after docking-based virtual screening were screened for their binding affinity with the other twelve related protein kinases [PDB IDs: 4D2S (DYRK1B), 3KVW (DYRK2), 3O0G (CDK5/p25), 5W4W (CK1), 1Z57 (CLK1), 3RAW (CLK3), 5OY4 (GSK3β), 2PZY (MAPK2), 3RTP (MAPK10), 5VUA (PIM1), 5LCP (PKA), and 1DSY (PKCα)]. Ligands with a Glide XP score less than −5 and Prime MM/GBSA binding free energy below −40 kcal/mol were rejected and considered to be non-selective. Among them, the compound Quercetin (molMall IDs: 22067) was found to have a high Glide XP score and binding free energy, with 10 out of 12 kinases. Various physicochemical and pharmacokinetic attributions (QP properties) of the selected 15 hit ligands were computed and equated with the eligibility limits as recommended for orally active CNS drugs [57] .

The computational toxicity webserver ProTox-II [58] was utilized to predict the toxicity profile of the selected potential six hits, having molMall IDs: 9539, 11352, 15938, 19037, 21830, and 21878. Despite the slight toxic probability of the three hits, all the six final hits were included for further MD simulation study, which confirmed their stability in the ATP pocket of DYRK1A kinase. Among the selected six hits, molecules having molmall ID 15938, 11352 and 21878 were also found to have affinity towards DYRK2, GSK3β, CLK1, CLK3 and MAPK10 protein kinases, in addition to DYRK1A. The molecules were predicted to be easily synthesizable. Therefore, their synthesis and kinase profiling are further warranted to establish them as selective DYRK1A inhibitors.

The molMall database, (MDPI database; URL: http://www.molmall.net/download. html; accessed on 16 September 2017), with 15,381 diverse chemical structures, was downloaded in SDF format and imported into Maestro (version 10.2), the graphical user interface (GUI) of Schrödinger computational software [66] . The application LigPrep (ver. 3.4) was used for the preparation of the docking library in maestro format, which includes the generation of a three-dimensional (3D) structure, energy minimization using OPLS 2005 force field, ionization at pH 7.0 ± 2.0 using ionizer, and the generation of the tautomers and stereoisomers. [33, [38] [39] [40] [41] [48] [49] [50] [51] [52] [53] [54] [55] [56] . Protein structures in PDB format were imported on Maestro workspace and prepared for docking by protein refinement tools available in workflows option. Protein structures were pre-processed and analysed. Bond orders were corrected, H atoms were appended, and H 2 O molecules, including any heteroatoms other than co-crystallized ligands, were excised. The H-bonding network in the protein structures were optimized by exhaustive sampling option and then, finally, the energy of the optimized structures was minimized to RMSD at 0.3 Å by Impref minimization option by using force field OPLS 2005. The refined and energy minimized protein structures in maestro format were used for the receptor grid (20 × 20 × 20 Å) generation to define the docking site by identifying the co-crystallized ligands, through Receptor Grid Generation of Glide available on applications panel. The grid file for each protein structure was subsequently exposed for docking.

The 2D structures of each co-crystallized ligand, viz. EHB (3ANQ), 3RA (4AZE), D15 (2WO6), 4E2 (4YLK), QIV (5A3X), DYK (4D2S), IRB (3KVW), 3O0 (3O0G), 9WG (5W4W), DBQ (1Z57), 3RA (3RAW), B4K (5OY4), B18 (2PZY), 34I (3RTP), 8GX (5VUA), M77 (5LCP), and PSF (1DSY), were drawn on ChemDraw Ultra (ver. 12.0) and saved in SDF format. These 2D structures in SDF format were imported into Maestro workspace and processed by the application LigPrep by the method discussed above. The prepared structures were docked into the ATP pocket of their corresponding receptor by Glide extra precision (XP) docking [67, 68] . The docked ligand exhibiting orientation similar to that of the co-crystallized ligands were saved and superimposed with the co-crystallized poses, in order to check the accuracy of the docking protocol.

Furthermore, the docking protocol was also validated by area under receiver operating characteristic (ROC) curves. Five known and potent DYRK1A inhibitors, namely INDY, a lamellarin D analogue, a quinazoline amine derivative, Leucettine L41, and harmine ( Figure 1) , were selective as a set of active inhibitors. These active inhibitors were used to generate 213 decoys (inactive inhibitors) online by using DUDE webserver (A Database of Useful Decoys: Enhanced) [45] . The decoys were enriched with the actives and all the 218 ligands were prepared and docked into the ATP binding pocket of five DYRK1A structures having PDB IDs viz. 2WO6, 3ANQ, 4AZE, 4YLK and 5A3X. The obtained CSV result files for each DYRK1A crystal structures having the docking scores were provided as an input file for the generation of ROC curves online by the webserver, screening explorer [46] .

Virtual screening workflow available in Schrödinger computational software [66] was used for docking-based virtual screening of the library comprising 54,594 structures, using the generated grid of five DYRK1A receptors, having PDB IDs viz. 3ANQ, 4AZE, 2WO6, 4YLK and 5A3X. For the virtual screening, HTVS (high-throughput virtual screening) with 1% output, SP (standard precision) with 10% output, and XP (extra precision) with 100% output docking mode options were selected. The common top scoring ligands obtained after virtual screening were saved in pdb format, along with their corresponding proteins for their binding pattern analysis.

The ligand-protein complexes of top scoring ligands were analysed by Biovia Discovery Studio Visualizer (v20.1.0.19295) [69] . Molecules having hydrogen bond interactions with key amino acid residues, such as Ile165, Lys188, Glu239, Leu241, Ser242, Asn244, and Asp307 of the target protein, were retained for binding free energy calculations. Twodimensional binding pattern diagrams were obtained and saved for the selected compounds by Discovery Studio Visualizer. Three-dimensional binding interaction pictures (surface and cartoon view) for the docked ligands were obtained from PyMOL Molecular Graphics System (v1.8.4.0, Schrödinger Inc., New York, NY, USA) [70] .

Prime (v4.0) MM-GBSA modules in Maestro-Schrödinger suite 2015.2 was utilized for the estimations of binding free energies (∆G bind ) of selected ligand-protein complexes, using default parameters (OPLS_2005 force field and VSGB solvent model), to remove false positive hits [71] . A more negative ∆G bind value designates durable interaction. The heatmap visualization of the binding energy of the six identified hits with all the studied kinases (DYRK1A and related kinases) was obtained by using GraphPad Prism (version 9.1.0). 

The QikProp 4.4 module of Maestro-Schrödinger suite 2015.2 was utilized for the estimation of thirty-five QikProp (QP) attributions of the selected ligands [72] . Chemical structures of the ligands were neutralized preceding to the estimation of QP attributions. The attributions were predicted and compared with the qualifying limits as proposed for orally active CNS drug discovery [57] .

The computational toxicity webserver ProTox-II was used to predict and compute the toxicity profile of selected hits [58] . Acute toxicity (oral, LD 50 ), hepatotoxicity, mutagenicity, carcinogenicity, cellular toxicity, immunotoxicity, and toxicological pathways (nuclear receptor signalling and stress response pathways) were computed, along with the accuracy of the prediction.

MD simulations were used to confirm the interactions, constancy, and activity of recognised ligand structures in the ATP pocket of human DYRK1A protein (PDB ID: 3ANQ), with reference to DYRK1A structure, co-crystallized with a benzothiazole derivative, EHB [33] . GROMACS 2018.1 package [73, 74] and the CHARMM36 all-atom force field were utilized for 100 ns MD simulations of chosen docked complexes [75] . Using the CHARMM General Force Field (CGenFF) tool, the topology and parameter files for the ligands were created [76] . After that, each docked complexes were solvated in an orthorhombic box using the four-point TIP4P water model [77] at a distance of at least 1 nm from the docked ligand and protein system. The system was neutralized and counterbalanced by adding nine chloride (Cl − ) ions. Furthermore, the ionic strength of the solution of the system was maintained by adding 0.15 M NaCl to realistically mimic the physiological conditions. During the MD simulation, periodic boundary conditions (pbc) were used. For energy minimization, a steepest descent method with a maximum step size of 0.01 nm and a tolerance of 1000 kJ/mol/nm was utilized. The Linear Constraint Solver (LINCS) method was utilized to limit bond lengths. The particle mesh Ewald (PME) technique was used to conduct electrostatic calculations. The system was equilibrated utilizing canonical ensembles NVT, followed by isothermal-isobaric ensemble (NPT) for 100 ps after energy reduction. All simulations were run at the same temperature and pressure (300 K, 1 atm). Trajectories were created every 2 fs and stored every 2 ps during the manufacturing run, which lasted 100 ns. GROMACS analysis programs were used to perform all preliminary analyses, comprising root mean square deviation (RMSD), radius of gyration (Rg), root mean square fluctuations (RMSF), potential binding energy, solvent-accessible surface area (SASA), hydrogen bond (H-bond), and principal component analysis (PCA).

The identified six hits and reported three inhibitors were submitted to the Swiss Target Prediction webserver (http://www.swisstargetprediction.ch/; accessed on 23 January 2022) [78] and molinspiration webserver (https://www.molinspiration.com/cgi-bin/ properties; accessed on 23 January 2022) [79] in order to determine their kinase inhibitory potential and bioactivity scores.

The structure similarity between the six identified hits and co-crystallized ligand structures of DYRK1A and related kinases were studied by ChemMine Web Tools (https:// chemminetools.ucr.edu/; accessed on 23 January 2022) [80] . The structures were clustered by hierarchical clustering. The structure similarity of six identified hits were compared with the co-crystallized ligand structures, and distance matrix (Z-scores) were computed. The heatmap visualization of distance matrix was prepared by using GraphPad Prism (version 9.1.0).

The synthetic accessibility (SA) prediction of the identified molecules was performed by SyntheticAccessibiliyCli (Ambit-SA) software tool (http://ambit.sourceforge.net/reactor. html; accessed on 5 February 2022) [81].

The discovery of selective and potent inhibitors of DYRK1A is an emerging field of investigation, as decades of research on neurodegenerative diseases, especially Alzheimer's Disease, have recognized DYRK1A as a novel drug target for therapeutic intervention.

In the present study, the molMall database, consisting of 15,381 rare, diverse and unique compounds, was screened by docking-based virtual screening against a set of five DYR1A protein kinases. Hydrogen bond interaction with Leu241 (gk+3) were considered key determinants for the selection. Binding free energies (∆G bind ) of selected ligand-protein complexes were also calculated in order to remove false positive hits. The high scoring selected ligands were further screened for their binding affinity with the other twelve DYRK1A-related protein kinases in order to find selective inhibitors. Among the identified ligands, a bis-indole indigoid scaffold (molMall ID: 19394) was already reported previously as a DYRK1A inhibitor. Various physicochemical and pharmacokinetic attributions, as well as the toxicity profile of the nominated six hit ligands, were also computed and were found to be satisfactory for orally active CNS drugs. The selected docked ligand-protein complexes were exposed to MD simulations to validate their mechanism of interactions and stability in the ATP pocket of human DYRK1A kinase. The 100 ns simulation time appeared to be suitable, and it is concluded that all the selected ligand structures having molMall IDs: 9539, 11352, 15938, 19037, 21830 and 21878 are potential inhibitors of the DYRK1A protein. Table S1 : Thirty-five physicochemical and pharmacokinetic properties of six identified hit molecules, predicted by QikProp (Schrodinger) for orally active CNS drugs, Table  S2 : Toxicity profile of six identified hit molecules, predicted by ProTox-II, Table S3 : Comparison of kinase inhibition bioactivity, predicted by Swiss Target Prediction and molinspiration webservers, of the identified 6 hit ligands and the reported 3 inhibitors, and Table S4 : Structural similarity analysis of six identified hits with the co-crystallized ligands of studied DYRK1A and related kinases by hier-archical clustering -distance matrix method (ChemMine Web Tools). 

The data presented in this study are available on request from the corresponding authors.

Where, when, and in what form does sporadic Alzheimer disease begin?

WHO. Dementia Fact Sheet

Benefits and Harms of Prescription Drugs and Supplements for Treatment of Clinical Alzheimer-Type Dementia

Genetic dissection of neurodegenerative disease

The importance of neuritic plaques and tangles to the development and evolution of AD

DYRK1A: A master regulatory protein controlling brain growth

Alzheimer disease therapy-moving from amyloid-β to tau

A new roadmap for drug development for Alzheimer's disease

The amyloid hypothesis, time to move on: Amyloid is the downstream result, not cause, of Alzheimer's disease. Alzheimer's Dement

MNB/DYRK1A as a multiple regulator of neuronal development

DYRK family of protein kinases: Evolutionary relationships, biochemical properties, and functional roles

Dyrk1A Phosphorylates p53 and Inhibits Proliferation of Embryonic Neuronal Cells

The role of DYRK1A in neurodegenerative diseases

Link Between DYRK1A Overexpression and Several-Fold Enhancement of Neurofibrillary Degeneration with 3-Repeat Tau Protein in Down Syndrome

Increased Dosage of Dyrk1A Alters Alternative Splicing Factor (ASF)-regulated Alternative Splicing of Tau in Down Syndrome

High-content siRNA screening of the kinome identifies kinases involved in Alzheimer's disease-related tau hyperphosphorylation

Dunckley, T. β-Carboline Compounds, Including Harmine, Inhibit DYRK1A and Tau Phosphorylation at Multiple Alzheimer's Disease-Related Sites

Regulation of RCAN1 Protein Activity by Dyrk1A Protein-mediated Phosphorylation

Dyrk1A-mediated phosphorylation of RCAN1 promotes the formation of insoluble RCAN1 aggregates

The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between β-amyloid production and tau phosphorylation in Alzheimer disease

Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: Evidence for a functional link between Down syndrome and Alzheimer's disease

Dyrk1A-mediated phosphorylation of Presenilin 1: A functional link between Down syndrome and Alzheimer's disease

DYRK1A Phosphorylates α-Synuclein and Enhances Intracellular Inclusion Formation

The selectivity of protein kinase inhibitors: A further update

The selectivity of inhibitors of protein kinase CK2: An update

QSAR analysis of pyrazolidine-3,5-diones derivatives as Dyrk1A inhibitors

Synthesis and biological activities of aminopyrimidyl-indoles structurally related to meridianins

Synthesis and biological evaluation of 3,6-diamino-1H-pyrazolo[3,4-b]pyridine derivatives as protein kinase inhibitors

Recent Advances in the Design, Synthesis, and Biological Evaluation of Selective DYRK1A Inhibitors: A New Avenue for a Disease Modifying Treatment of Alzheimer's?

Green Tea Polyphenols Rescue of Brain Defects Induced by Overexpression of DYRK1A

Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation

Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A

Synthesis and evaluation of β-carboline derivatives as potential monoamine oxidase inhibitors

Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosinephosphorylation-regulated kinases (Dyrk)

Structural features underlying the selectivity of the kinase inhibitors NBC and dNBC: Role of a nitro group that discriminates between CK2 and DYRK1A

Synthesis of chromeno[3,4-b]indoles as Lamellarin D analogues: A novel DYRK1A inhibitor class

Cocrystal Structures, and Neuroprotective Properties of Leucettines, a Family of Protein Kinase Inhibitors Derived from the Marine Sponge Alkaloid Leucettamine B

Structures of Down Syndrome Kinases, DYRKs, Reveal Mechanisms of Kinase Activation and Substrate Recognition

10-Iodo-11H-indolo[3,2-c]quinoline-6-carboxylic Acids Are Selective Inhibitors of DYRK1A

Probing the ATP-Binding Pocket of Protein Kinase DYRK1A with Benzothiazole Fragment Molecules

Novel Scaffolds for Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase (DYRK1A) Inhibitors

Structure-Guided Discovery of Potent and Selective DYRK1A Inhibitors

Validation of Molecular Docking Programs for Virtual Screening against Dihydropteroate Synthase

Directory of Useful Decoys, Enhanced (DUD-E): Better Ligands and Decoys for Better Benchmarking

Screening Explorer-An Interactive Tool for the Analysis of Screening Results

Synthesis and Kinase Inhibitory Activity of Novel Substituted Indigoids

Discovery and Optimization of a Novel Series of Dyrk1B Kinase Inhibitors to Explore a MEK Resistance Hypothesis

Defining Cdk5 Ligand Chemical Space with Small Molecule Inhibitors of Tau Phosphorylation

Identification and Profiling of a Selective and Brain Penetrant Radioligand for in Vivo Target Occupancy Measurement of Casein Kinase 1 (CK1) Inhibitors

Kinase Domain Insertions Define Distinct Roles of CLK Kinases in SR Protein Phosphorylation

From PIM1 to PI3Kδ via GSK3β: Target Hopping through the Kinome

The discovery of carboline analogs as potent MAPKAP-K2 inhibitors

Design and synthesis of brain penetrant selective JNK inhibitors with improved pharmacokinetic properties for the prevention of neurodegeneration

Theoretical Analysis of Activity Cliffs among Benzofuranone-Class Pim1 Inhibitors Using the Fragment Molecular Orbital Method with Molecular Mechanics Poisson-Boltzmann Surface Area (FMO+MM-PBSA) Approach

Ca(2+) bridges the C2 membrane-binding domain of protein kinase Calpha directly to phosphatidylserine

Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery

ProTox-II: A webserver for the prediction of toxicity of chemicals

Structure and Function of p53-DNA Complexes with Inactivation and Rescue Mutations: A Molecular Dynamics Simulation Study

Identification of phytochemical inhibitors against main protease of COVID-19 using molecular modeling approaches

Myriad stumbles, Wyeth closes on Alzheimer's

Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: A randomized controlled trial

Alzheimer's failure raises questions about disease-modifying strategies

Strategies, Development, and Pitfalls of Therapeutic Options for Alzheimer's Disease. J. Alzheimer's Dis

Kinase selectivity potential for inhibitors targeting the ATP binding site: A network analysis

Version 10.2; Schrödinger LLC

Glide, Version 6.7; Schrödinger LLC

Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes

Biovia Discovery Studio Visualizer

GROMACS: Fast, flexible, and free

Algorithms for highly efficient, load-balanced, and scalable molecular simulation

Optimization of the Additive CHARMM All-Atom Protein Force Field Targeting Improved Sampling of the Backbone φ, ψ and Side-Chain χ 1 and χ 2 Dihedral Angles

Automation of the CHARMM General Force Field (CGenFF) II: Assignment of Bonded Parameters and Partial Atomic Charges

Development of an improved four-site water model for biomolecular simulations: TIP4P-Ew

SwissTargetPrediction: Updated data and new features for efficient prediction of protein targets of small molecules

ChemMine tools: An online service for analyzing and clustering small molecules

Acknowledgments: Abuzer Ali is thankful to Taif University Researchers Supporting Project Number (TURSP-2020/124), Taif University, Taif, Saudi Arabia.

The authors declare no conflict of interest.